RNA interference (RNAi) is a powerful strategy for unraveling gene function and for drug target validation, but exogenous expression of short hairpin RNAs (shRNAs) has been associated with severe side effects. These may be caused by saturation of the microRNA pathway. This study shows degenerative changes in cell morphology and intrusion of blood vessels after transduction of the ventromedial hypothalamus (VMH) of rats with a shRNA expressing adeno-associated viral (AAV) vector. To investigate whether saturation of the microRNA pathway has a role in the observed side effects, expression of neuronal microRNA miR-124 was used as a marker. Neurons transduced with the AAV vector carrying the shRNA displayed a decrease in miR-124 expression. The decreased expression was unrelated to shRNA sequence or target and observed as early as 1 week after injection. In conclusion, this study shows that the tissue response after AAV-directed expression of a shRNA to the VMH is likely to be caused by shRNA-induced saturation of the microRNA pathway. We recommend controlling for miR-124 expression when using RNAi as a tool for studying (loss of) gene function in the brain as phenotypic effects caused by saturation of the RNAi pathway might mask true effects of specific downregulation of the shRNA target.
INTRODUCTION
RNA interference (RNAi) has become a very powerful and widely used technique for both determination of gene function and drug target validation. The specificity of post-transcriptional gene silencing has allowed for the design of precise targeting tools. Despite the successful application of RNAi to animal models of disease, there is emerging evidence linking high-level short hairpin RNA (shRNA) expression to cellular toxicity. An increasing number of reports reveal dramatic adverse effects after shRNA delivery in vivo regardless of tissue type or animal species. Adverse effects of shRNAs have been described in dog heart, 1 in mouse liver, [2] [3] [4] in several mouse brain regions such as striatum 5, 6 and cerebellum 7 and in rat ventral tegmental area/substantia nigra 8, 9 and red nucleus. 10 These toxic effects have been attributed to activation of innate immunity via induction of an interferon response, 11 off-target effects 12 and saturation of the microRNA pathway. 2 Viral vector-mediated overexpression or knockdown of genes is also a promising approach to unravel the role of genes implicated in energy balance. We have gained novel insights into the role of genes in bodyweight regulation by overexpressing the neuropeptides agouti-related peptide and neuropeptide Y using adenoassociated virus (AAV). 13, 14 AAV expression constructs were also developed for stable expression of shRNAs targeting obesityrelated genes, including the fat mass and obesity-associated protein (FTO). 15 In order to address whether this specific approach induces toxicity, we performed a morphological analysis of neuronal degeneration using cresyl violet staining. We show the importance of using expression of neuron-specific microRNA miR-124 as tool to investigate whether toxic effects are due to saturation of the microRNA pathway.
RESULTS AND DISCUSSION
The aim of the present study was to examine putative adverse effects of viral vector-mediated RNAi and to find a reliable method to determine toxicity due to saturation of the microRNA pathway. Five different FTO-targeting shRNA sequences were cloned into an AAV2 vector. A dual luciferase assay was performed to measure FTO knockdown by the different pAAV-sh-FTO constructs in vitro (Supplementary Figure S1) . pAAV-sh-FTO#1 (further referred to as pAAV-sh-FTO) was selected for further study because of its 87% silencing efficacy (Po0.01).
pAAV-sh-FTO was encapsidated into an AAV1 coat and stereotactically injected into the ventromedial hypothalamus (VMH). Eight animals received AAV-sh-FTO and their brains were analyzed six weeks after injection. The viral vector contained a green fluorescent protein (GFP) cassette allowing the transduced area to be precisely identified. An in situ hybridization (ISH) to detect GFP mRNA expression and a cresyl violet staining were used to analyze transduction efficiency and to detect potential toxicity, respectively. Analysis of GFP expression indicated that the hypothalamic area was efficiently transduced by AAV-sh-FTO (Figures 1a, c and e) . However, cresyl violet staining revealed an adverse tissue reaction in the VMH in response to the injection of AAV-sh-FTO, as indicated by the degenerative changes in tissue morphology (n ¼ 3) (Figure 1b) or by intrusion of blood vessels (n ¼ 3) (Figure 1d ). This was similar to Ehlert et al. 10 who used shRNAs targeting neuropilins in the red nucleus. Surprisingly, some brains of rats injected with the same amount of particles of the same viral prep appeared not to display an adverse tissue reaction (n ¼ 2) (Figure 1f ), indicating that either the AAV-sh-FTO did not always induce toxicity or it was not always visible after cresyl violet staining. The observed differences in morphological changes might be explained by variation in the number of genomic copies that transduced the cells. Higher copy numbers could lead to increased toxicity.
Adverse effects after exogenous shRNA expression have been attributed to induction of an interferon response, massive offtarget effects and saturation of the microRNA pathway. 2, 11, 12, 16 As there were signs of toxicity, we focused on the saturation of the microRNA pathway as a possible cause of the observed adverse tissue reaction. It has been reported that viral vector-mediated expression of shRNAs may lead to downregulation of endogenous microRNAs both in vitro 17 and in vivo. 2, 3 Expression of the endogenous neuronal microRNA miR-124 was analyzed to determine whether shRNA expression lead to saturation of the microRNA pathway. Cells transduced by AAV-sh-FTO showed a 62% decrease in miR-124 expression (Figures 2a and b) . The sites where GFP was expressed, indicating infected cells, do not express miR-124, whereas there was ubiquitous expression of miR-124 in non-infected regions. To exclude the possibility that the observed toxicity is due to off-target effects by pAAV-sh-FTO or due to FTO knockdown, the non-targeting pAAV-sh-Con was also included. The overexpression construct pAAV-GFP was used to investigate whether AAV infection or GFP expression could result in toxicity. Figure S4) .
To learn more about shRNA-induced saturation of the microRNA pathway and its timeline, six rats received a unilateral injection of AAV-sh-FTO in the VMH. AAV-GFP was injected in the other side, so rats could serve as their own control. Rats were killed 1, 2 and 5 weeks after injection, and their brains were analyzed for miR-124 and NeuN expression. After injection of AAV-sh-FTO in the VMH, a trend towards decreased miR-124 expression could be observed after only 1 week (Figure 3b) . At 5 weeks, miR-124 expression was decreased to 9±7.9% of control side (Figures 3h and j) . Expression of FTO shRNA correlated strongly with reduction in miR-124 expression (Figures 3c, f and i) .
In none of the rats injected with AAV-sh-FTO or AAV-sh-Con into the VMH, body weight or food intake was affected (data not shown). This is in contrast to Tung et al. 18 who showed that expression of FTO shRNA in mice resulted in increased food intake. They targeted the arcuate nucleus, which is in close proximity to the VMH, and this may be a more important site for FTO to have a physiological role in energy balance than the VMH. However, Tung et al. 18 did not report on toxicity, and the control used consisted of a scrambled shRNA.
Our findings provide further evidence that the endogenous microRNA machinery is perturbed by shRNA overexpression. Consistent with previous findings, this decrease in endogenous microRNA expression is unrelated to shRNA sequence or target and is not observed after GFP overexpression. 10 Some studies report neuronal degeneration upon shRNA delivery, 6 whereas others report a decrease in microRNA expression. 2 This study demonstrates that within one animal both neuronal degeneration, assessed by loss of NeuN staining, and a decrease in microRNA expression in surviving neurons, assessed by miR-124 staining, can be observed (Figures 2f and f') . Whether a neuron survives the saturation of the microRNA pathway might be dependent on the variation in number of genomic copies in transduced cells and the activity of the endogenous miRNA pathway. 17 These results indicate that the oversaturation of the microRNA machinery is progressive and precedes neuronal degeneration. Therefore, we cannot exclude that the lack of histologically visible toxicity after shRNA overexpression (such as shown in Figure 1 ) is due to a modest interference of endogenous microRNA expression that may develop over time.
As the downregulation of endogenous microRNAs is also seen in brains without morphological changes, these results indicate that lack of morphological changes or neuronal loss does not implicate that shRNA expression does not cause severe side effects. microRNAs function by targeting a variety of 3 0 untranslated regions of genes. Depending on the specific role of microRNAs in a given cell, a certain phenotypic effect will be induced. This effect might subsequently be attributed to the downregulation of the shRNA target. Besides cresyl violet and NeuN staining, expression of endogenous microRNAs appears to be a good marker for neuronal health after expression of shRNAs. We propose to use tissue-specific endogenous microRNAs as markers to exclude saturation of the microRNA pathway in studies of shRNA-mediated knockdown of genes. Care should be taken in interpreting results obtained from studies lacking these controls. [19] [20] [21] Based on in vitro studies, Exportin-5 and Argonaute-2 are most likely the two components of the microRNA pathway to be saturated by exogenous shRNA expression. The karyopherin Exportin-5 is responsible for nuclear export of both shRNAs and pre-miRNAs. 22, 23 Exogenous shRNAs can compete with premiRNAs for binding Exportin-5 leading to inhibition of miRNA function. 17 The consequences of this saturation can be relieved by overexpression of Exportin-5, enhancing both shRNA-and microRNA-induced RNAi in vitro 17,24 and in vivo. 2 As Exportin-5 expression is relatively low in the brain, 17 it is proposed that this makes this organ particularly sensitive to saturation of Exportin-5. 10 Within the cytoplasm, RNAi-induced silencing complex component Argonaute-2 is responsible for microRNA biogenesis and binding and cleavage of target mRNA. Overexpression of Argonaute-2 results in enhanced RNAi mediated by shRNAs and miRNAs. 24 The specificity of RNAi allows for the design of very precise targeting tools, which may have the potential to be used as a therapeutic strategy. It is of importance in the use of RNAi for clinical applications to prevent saturation of the microRNA pathway by shRNAs without comprising their therapeutic efficacy. Possible strategies to relieve the saturation of microRNA pathways by exogenous shRNA expression include lowering the dose, 8, 10 the use of a less efficient or regulatable promoter, 25 changing viral vector serotype 10 or placing the shRNA into a microRNA background. 5, 7 In summary, this study demonstrates the presence of an adverse tissue response after AAV1 administration to the VMH, which is likely to be caused by shRNA-induced saturation of the microRNA pathway. Decreased expression of endogenous microRNAs is evident 1 week after injection of the virus, and this decrease aggravates in time. In animal models of disease, these lowered levels of microRNA expression might lead to an incorrect interpretation of results. It is therefore important to carefully examine the expression of tissue-specific endogenous microRNAs as markers to be able to exclude potential toxicity due to saturation of the microRNA pathway.
MATERIALS AND METHODS

Cell lines
Human embryonic kidney (HEK) 293T cells were cultured at 37 1C with 5% CO 2 in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FCS) (Lonza, Basel, Switzerland), 2 mM glutamine (PAA, Cö lbe, Germany), 100 units ml À 1 penicillin (PAA), 100 units ml À 1 streptomycin (PAA) and non-essential amino acids (PAA).
AAV plasmids
All pAAV-shRNA constructs were designed by cloning oligonucleotides into the AAV2 vector pAAV-Base. The viral vector contained a GFP cassette to precisely identify the transduced area. Experiments were conducted using shRNAs targeting FTO (pAAV-sh-FTO), a control shRNA without an endogenous mRNA target (pAAV-sh-Con) and a GFP expression vector without shRNA (pAAV-GFP). pAAV-Base and pAAV-sh-Con were a kind gift from RJ DiLeone. 21 pAAV-sh-FTO plasmids were cloned as previously described. 26 Bioinformatics tools from Biopredsi (Qiagen, Valencia, CA, USA) and Invitrogen were used to identify shRNA sequences targeting FTO. Five sets of oligonucleotides were synthesized for cloning ( Table 1) . The oligonucleotides had XbaI and SapI overhangs to allow for ligation into the pAAV-Base. Cloning of AAV-GFP was previously described. 27 All constructs were verified by sequencing.
cDNA-Renilla fusion construct
Rat FTO cDNA was obtained by PCR amplification using B1 and B2 gateway primers on hypothalamic rat cDNA ( Table 1 ). The cassette was recombined with pDONR201 (Invitrogen) to generate pENTR201-FTO. This construct was subsequently recombined with pBabe-puro (Invitrogen) containing Renilla Luciferase cDNA to generate the cDNA-Renilla fusion plasmid pBabe-FTO-Renilla. All constructs were verified by sequencing.
Luciferase assay HEK293T cells in a 24-well plate were transfected with 5 ng pcDNA4/TOluc, 500 ng pBabe-FTO-Renilla and 1500 ng pAAV-shRNA or pAAV-Base using polyethylenimine (Polysciences, Eppelheim, Germany). Three days after transfection, cells were lysed, and Renilla Luciferase activity was assessed. Values were corrected for transfection efficiency using Firefly Luciferase activity and normalized to pAAV-Base knockdown.
Virus production and purification
Virus was generated and purified as previously described. 26 HEK293T cells were co-transfected in 15 15 Â 15 cm 2 dishes with pAAV-shRNA or pAAV-GFP and pDP1 (Plasmid Factory, Bielefeld, Germany) using Table 1 . Oligonucleotides used in this study shRNA-induced saturation of the microRNA pathway MA van Gestel et al polyethylenimine. Sixty hours after transfection, cells were collected, pelleted and resuspended in ice cold buffer (150 mM NaCl, 50 mM Tris, pH 8.4). Cells were lysed by three freeze-thaw cycles and incubated for 30 min at 37 1C with 50 U ml À 1 Benzonase (Sigma, Zwijndrecht, The Netherlands). The lysate was loaded onto a 15, 25, 40 and 60% iodixanol gradient. After centrifugation at 70.000 r.p.m. for 60 min at 18 1C, the 40% layer was extracted and used for ion-exchange chromatography. AAV-positive fractions were determined by quantitative PCR for GFP RNA (Table 1) and concentrated using an Amicon Ultra 15 ml filter (Millipore, Amsterdam, The Netherlands). Titer was determined by quantitative PCR for GFP RNA (Table 1) .
Animals
Male Wistar rats (Charles River, Germany) were housed in filter top cages in a temperature-and humidity-controlled room temperature (RT) 21 ± 2 1C and humidity 55 ± 5% with a 12-h light/dark cycle. All experimental procedures were approved by the Committee for Animal Experimentation of the University of Utrecht (Utrecht, The Netherlands).
Surgical procedures
Rats were anesthetized using fentanyl/fluanisone and midazolam and mounted onto a stereotaxic apparatus. Virus was administered by placing syringe needles into the VMH (coordinates from Bregma: À 2.1 AP, þ 1.5 ML, À 9.9 DV, at a 51 angle). A total of 1.5 ml of virus (8.4 Â 10 11 gc ml À 1 ) was injected at a rate of 0.2 ml min For the ISH, sections were pre-hybridized in hybridization solution (50% formamide, 5 Â SSC, 5 Â Denhardts, 250 mg ml À 1 tRNA Baker's yeast, 500 mg ml À 1 sonicated salmon sperm DNA) for 2 h at RT. The hybridization solution containing 400 ng ml À 1 720-bp long digoxigenin (DIG)-labeled enhanced GFP riboprobe (antisense to NCBI gene DQ768212) was then applied to the slides followed by overnight incubation at 68 1C.
After a quick wash in 68 1C pre-warmed 2 Â SSC, slides were transferred to 68 1C pre-warmed 0.2 Â SSC for 2 h. After blocking for 1 h with 10% FCS in B1 (0.1 M Tris pH 7.5/0.15 M NaCl), DIG was detected with an alkaline phosphatase-labeled antibody (1:5000, Roche, Mannheim, Germany) after overnight incubation at RT using NBT/BCIP as a substrate. Sections were dehydrated in ethanol, cleared in xylene and embedded in Entellan.
The LNA ISH hybridization is performed as previously described. 28 Briefly, sections were pre hybridized in hybridization solution (50% formamide, 5 Â SSC, 5 Â Denhardts, 200 mg ml À 1 tRNA Baker's yeast, 500 mg ml À 1 sonicated salmon sperm DNA, 0.02 g ml À 1 Roche blocking reagent) for 1 h at RT. Hybridization was performed with 10 nM double-DIG (3 0 and 5 0 )-labeled LNA probe for human miR-124 or miR-138 (Exiqon, Denmark) or with 20 nM double-DIG (3 0 and 5 0 )-labeled LNA probe for the shFTO (Exiqon, Vedbaek, Denmark) for 2 h at 55 1C. After a quick wash in 60 1C pre-warmed 5 Â SSC, slides were transferred to 60 1C pre-warmed 0.2 Â SSC for 2 h. After blocking for 1 h with 10% FCS in B1 (0.1 M Tris pH 7.5/0.15 M NaCl), DIG was detected with an alkaline phosphatase-labeled antibody (1:2500, Roche) after overnight incubation at RT using NBT/BCIP as a substrate. Slides were further processed for immunohistochemistry.
Immunofluorescent labeling
Sections were blocked using 1% FCS in PBS/0.2% TritonX100 for 1 h at RT. Next, mouse anti-NeuN (1:200, Millipore) diluted in blocking solution was applied to the sections for overnight incubation at 4 1C. After washing in PBS, sections were incubated in secondary antibody goat-anti-mouse Alexa 594 (1:600, Invitrogen) in blocking solution. Images were taken using Axioscope A1 fluorescence and Axioskop 2 microscopes (Carl Zeiss, Gö ttingen, Germany).
ImageJ software (National Institutes of Health, Bethesda, MD, USA) was used to quantify miR-124 expression in VMH neurons.
